| ambrisentan / Generic mfg. |
2016-004806-32: Right ventriculAr reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES) Rimodellamento inverso del ventricolo destro e miglioramento emodinamico dopo aggiunta della terapia di combinazione (ambrisentan/inibitori della PDE-5) in pazienti con ipertensione polmonare arteriosa |
|
|
| Not yet recruiting | 4 | 54 | Europe | Volibris, [EU/1/08/451/004], Film-coated tablet, na | ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET, Glaxo Smith Kline S.p.A, Glaxo Smith Kline S.p.A. Italia | patients with pulmonary arterial hypertention pazienti con ipertensione polmonare arteriosa, patients with pulmonary arterial hypertention pazienti con ipertensione polmonare arteriosa, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000034898: Transition from Ambrisentan to Macitentan in Pulmonary Arterial Hypertension: a Prospective Observational Study |
|
|
| Not yet recruiting | 4 | 100 | | Case series | Second Xiangya Hospital of Central South University; Second Xiangya Hospital of Central South University, The National Natural Science Foundation of China | Pulmonary arteral hypertension | | | | |
ACTRN12607000170426: Safety and Efficacy Study of Ambrisentan in Subjects with Pulmonary Hypertension |
|
|
| Completed | 3 | 200 | | | Gilead Sciences, Inc., Gilead Science, Inc. | Pulmonary Hypertension | | | | |
ChiCTR2400080435: A Study to Assess the Effects of the Endothelin Receptor Antagonist Ambrisentan, the SGLT2 Inhibitor Henagliflozin, and Their Combination in Patients With IgA Nephropathy: a Single-center, Randomized, Open-label, Cross-over Clinical Trial |
|
|
| Not yet recruiting | 3 | 60 | | "ambrisentan"-"henagliflozin"-"ambrisentan+henagliflozin"; "ambrisentan"-"ambrisentan+henagliflozin"-"henagliflozin"; "henagliflozin"-"ambrisentan"-"ambrisentan+henagliflozin"; "henagliflozin"-"ambrisentan+henagliflozin"-"ambrisentan"; "ambrisentan+henagliflozin"-"henagliflozin"-"ambrisentan"; "ambrisentan+henagliflozin"-"ambrisentan"-"henagliflozin" | Peking University First Hospital; Peking University First Hospital, National Science Fund for Distinguished Young Scholars (No. 81925006) | IgA Nephropathy | | | | |
| Completed | 2/3 | 454 | Europe | EDP1815, Dapagliflozin, Forxiga, Ambrisentan, Letairis, Volibris, Pulmonext, Standard of care | Cambridge University Hospitals NHS Foundation Trust | COVID-19 | 06/22 | 06/22 | | |
2007-005679-33: Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis Einfluss des selektiven Endothelin-Rezeptorblockers Ambrisentan auf den portalen Druck bei Patienten mit Zirrhose |
|
|
| Ongoing | 2 | 24 | Europe | Volibris 10 mg, Volibris 10 mg | Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg, Martin-Luther-Universität Halle Wittenberg | Portal hypertension and hepatic cirrhosis Portale Hypertonie und Leberzirrhose | | | | |
2011-001139-22: Treatment of portopulmonary hypertension (high blood pressure in the pulmonary circulation) with ambrisentan (a medicinal product for the therapy of portopulmonary hypertension). |
|
|
| Ongoing | 2 | 12 | Europe | Ambrisentan, Volibris 5 mg Filmtabletten, Volibris 5 mg Filmtabletten | Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie, Glaxo Smith Kline | Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated and improves hemodynamics as well as symptoms and physical capacity. | | | | |
| Terminated | 2 | 88 | Europe, RoW | Ambrisentan, N-003 (ambrisentan solution), Placebo, Propylene glycol | Noorik Biopharmaceuticals AG, Noorik Biopharmaceuticals AG. | Covid19, Hypoxemia | 02/23 | 02/23 | | |
NCT06256432: Endothelin Receptor Antagonism with Ambrisentan to Treat Hepatorenal Syndrome |
|
|
| Recruiting | 2 | 54 | RoW | Ambrisentan, Terlipressin | Noorik Biopharmaceuticals AG | Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic | 12/25 | 02/26 | | |
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation |
|
|
| Not yet recruiting | 2 | 36 | Europe, Canada, US | Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin | University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals | Type 1 Diabetes Mellitus With Diabetic Nephropathy | 03/25 | 03/25 | | |
NCT04528056: Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension |
|
|
| Recruiting | 1/2 | 80 | RoW | Sulfasalazine, Ambrisentan, Sulfasalazine's placebo, Ambrisentan's placebo | RenJi Hospital | Pulmonary Arterial Hypertension | 12/21 | 10/22 | | |
ChiCTR-IIR-16009795: An open label, randomized, single-dose, two-period, two-sequence, crossover pivotal study to assess the bioequivalence of Ambrisentan Tablets 5mg in healthy adult subjects under fasting/ Fed condition |
|
|
| Not yet recruiting | 1 | 30 | | The first cycle of fasting to take the test preparation; the second cycle of fasting reference preparation; the third cycle of fasting to take the test preparation; the fourth cycle of fasting reference preparation; ;The first cycle of fasting reference preparation; the second cycle of fasting reference preparation; the third cycle of fasting reference preparation; the fourth cycle of fasting reference preparation | The First Hospital of Jilin University; CTTQ, CTTQ | pulmonary hypertension | | | | |
2019-001699-12: Relative bioavailability study of marketed and lower dose ambrisentan in healthy adult participants |
|
|
| Not yet recruiting | 1 | 24 | Europe | Ambrisentan Tablet, Ambrisentan 5mg film-coated tablets [marketed product], GSK1325760, Tablet, Film-coated tablet, Volibris | GlaxoSmithKline Research and Development Ltd, GlaxoSmithKline Research & Devlopment Ltd | Pulmonary arterial hypertension, Pulmonary arterial hypertension (a narrowing of the arteries connecting the lungs to the heart that leads to an increase in blood pressure), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-OON-17013521: Transition from ambrisentan to bosentan in pulmonary arterial hypertension: A single center prospective study |
|
|
| Completed | N/A | 20 | | oral ambrisentan ;oral bosentan | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Self financing | pulmonary arterial hypertension | | | | |
ChiCTR1900025197: An observational study assessing the transition from Ambrisentan to Bosentan in patients with pulmonary arterial hypertension |
|
|
| Recruiting | N/A | 43 | | drug transition | Second Xiangya Hospital of Central South University; Second Xiangya Hospital of Central South University, National Natural Science Foundation of China | pulmonary artery hypertension | | | | |
TAPE, NCT04972656: Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension |
|
|
| Recruiting | N/A | 420 | RoW | Ambrisentan, Placebo | Nanjing First Hospital, Nanjing Medical University, Tianjin Medical University General Hospital | Pulmonary Arterial Hypertension | 12/25 | 03/26 | | |
